Mike Cernovich may be emerging as the new Bannon in the alt-right movement. Vanity Fair's Tina Nguyen discusses his political strategy and how badly Bannon is perceived among the alt-right these days. Nguyen talks about Cernovich's motivation behind his theories. She says he is not foreign policy-minded and likes to just attack liberal ideology. He's also against most media outlets, even though he just put in a bid for Gawker.com. Despite his less-than-popular views, could he continue to gain popularity? Nguyen said in her conversation with him about buying Gawker he said, it "would be fun to own Gawker properties." She believes that was more as a taunt to the writers. But overall, she does believe he could continue to gain followers.

Share:
More In Politics
Biden Thanks 'Tennessee Three' for 'Standing Up' for Gun Control
Three Tennessee lawmakers who became Democratic heroes for facing expulsion after participating in gun control protests visited the White House on Monday, describing themselves as “representatives of a movement" that is demanding greater restrictions on firearms to save lives.
Speaker McCarthy Faces Big Test as Debt Bill Heads for Vote
Speaker Kevin McCarthy is hurtling toward one of the most consequential weeks of the new House Republican majority as he labors to pass a partisan package that would raise the nation's debt limit by $1.5 trillion in exchange for steep cuts that some in his own party oppose.
Biden Announces 2024 Reelection Bid: 'Let’s Finish This Job'
President Joe Biden on Tuesday formally announced that he is running for reelection in 2024, asking voters to give him more time to “finish this job” he began when he was sworn into office and to set aside their concerns about extending the run of America’s oldest president for another four years.
Supreme Court Set to Decide on Abortion Pill Access
The Supreme Court is facing a self-imposed Friday night deadline to decide whether women’s access to a widely used abortion pill will stay unchanged until a legal challenge to its Food and Drug Administration approval is resolved.
Load More